“Through these 2 small punctures, we can manipulate the device with the methodology to sample the entire prostate, both anterior apical and the posterior regions, where we find the vast majority of our cancers,” says Matthew A. Allaway, MD.
In this video, Matthew J. Allaway, MD, discusses the The PrecisionPoint Transperineal Access System, a new and efficient methodology for detecting prostate cancers in patients. Allaway is the founder and president of Perinealogic, urologist and managing partner at Urology Associates, Cumberland, Maryland.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.